Your browser doesn't support javascript.
loading
Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis.
Rasmussen, Daniel G K; Hansen, Michael K; Frederiksen, Peder; Luo, Yunyun; Pehrsson, Martin; Neal, Bruce; Karsdal, Morten A; Genovese, Federica.
Afiliación
  • Rasmussen DGK; Nordic Bioscience, Herlev, Denmark.
  • Hansen MK; Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
  • Frederiksen P; Nordic Bioscience, Herlev, Denmark.
  • Luo Y; Nordic Bioscience, Herlev, Denmark.
  • Pehrsson M; Nordic Bioscience, Herlev, Denmark.
  • Neal B; The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
  • Karsdal MA; The Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia.
  • Genovese F; Imperial College London, London, UK.
Diabetes Obes Metab ; 26(9): 4060-4068, 2024 Sep.
Article en En | MEDLINE | ID: mdl-39014523
ABSTRACT

AIM:

To investigate type III collagen (COL III) turnover in participants from the CANVAS Program biomarker substudy.

METHODS:

Biomarkers of COL III formation (PRO-C3) and COL III degradation fragments (C3M and CTX-III) were assessed in baseline and year 3 plasma from patients enrolled in CANVAS, investigating the effect of canagliflozin in participants with type 2 diabetes. The clinical outcomes investigated in this study were hospitalization for heart failure, cardiovascular death and all-cause mortality.

RESULTS:

Higher levels of PRO-C3 and C3M at baseline were associated with an increased incidence of all investigated outcomes, whereas levels of CTX-III at baseline were not associated with any of the investigated outcomes. Levels of PRO-C3 decreased and levels of CTX-III increased following canagliflozin treatment. An increase from baseline to year 3 in PRO-C3 in the placebo arm was associated with an increased incidence of cardiovascular outcomes, and in all participants was associated with an increased risk of all-cause mortality.

CONCLUSIONS:

The changes in PRO-C3 and CTX-III reflect a shift in the dynamics of COL3 turnover following treatment with canagliflozin. These biomarkers are promising pharmacodynamic tools that can be used to monitor the impact of canagliflozin treatment and possibly other sodium-glucose co-transporter-2 inhibitors on tissue remodelling in future interventional trials.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores / Colágeno Tipo III / Diabetes Mellitus Tipo 2 / Canagliflozina / Inhibidores del Cotransportador de Sodio-Glucosa 2 Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2024 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores / Colágeno Tipo III / Diabetes Mellitus Tipo 2 / Canagliflozina / Inhibidores del Cotransportador de Sodio-Glucosa 2 Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2024 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Reino Unido